EVO News & Events

Evotec announced the nomination of a small molecule preclinical development candidate from its multi-target drug discovery alliance in medical dermatology with Almirall. The program is aimed at developing novel treatments for immune-mediated inflammatory skin diseases with high unmet medical need. Evotec will continue to support the program toward IND submission through its INDiGO platform, an integrated, accelerated IND-enabling platform designed to ensure a transition from discovery to clinical readiness.

Evotec announced that it has received two grants from the Gates Foundation for drug discovery and translation in tuberculosis, following four earlier TB grants from the foundation, amounting to $4.9M over 25 months and $5M over 24 months. The grant programs will expand the pipeline of TB drug candidates and advance the most promising combinations toward clinical evaluation, reducing development risk.

Evotec announced that CFO Paul Hitchin will step down on April 30 for personal reasons unrelated to the company. The supervisory board has accepted Hitchin's decision. Hitchin will be succeeded by Claire Hinshelwood, effective May 1. Hinshelwood has more than 30 years of experience in financial leadership positions, most recently as group CFO of BMI Group.